TAME: testing whether metformin can delay a cluster of age-related diseases
The description presents TAME as a planned multi-center trial of about 3,000 people that would test whether metformin delays a cluster of age-related conditions and whether aging itself can be treated as a medical condition. As of early 2026 it had not fully happened, and funding was the main hurdle. [1]
Automatic summary · not editorially reviewed
The key findings
The description says TAME's core goal is to show that aging can be a treatable medical condition in the eyes of the FDA, not to prove metformin is a miracle drug. [1]
TAME's planned composite primary endpoint measures time until any one of a cluster of age-related conditions, including cardiovascular disease, cancer, dementia or death. [1]
As of early 2026 TAME had not fully happened; funding the $50M+ multi-center, 3,000-person trial was the primary hurdle, and smaller trials showed mixed results. [1]
The source at a glance
- Study type / format
- Video description of a planned multi-center trial and related smaller trials
- Population / context
- People in the planned TAME trial (about 3,000) and participants in smaller metformin trials such as MILES and MET-PREVENT, including already-frail seniors.
- Summary based on
- Creator description
- Original publication
- March 1, 2026
TAME's regulatory goal for aging as a condition
According to the description, TAME (Targeting Aging with Metformin) is often called the "Holy Grail" of geroscience, not mainly because of the drug but because of the regulatory precedent it seeks. The stated core goal is not to prove metformin is a miracle drug, but to show that "aging" can be a treatable medical condition in the eyes of the FDA. The description notes that the FDA currently approves drugs for specific diseases such as cancer or heart disease, and that TAME aims to show a single drug can delay a cluster of age-related diseases.
Supporting source [1]
Planned endpoints: disease cluster, walking speed, biological clocks
The description says TAME will use a composite primary endpoint measuring the time until a participant develops any one of a cluster of age-related conditions, including cardiovascular disease, cancer, dementia or death. Grouping these is meant to test whether a single intervention can delay multiple chronic diseases at once. Secondary endpoints are said to track functional markers such as walking speed and biological "clocks", to see whether the drug preserves physical independence and slows the underlying rate of aging.
Supporting source [1]
Status in early 2026 and mixed smaller-trial evidence
As of early 2026, the description states TAME remains the most influential trial that has not fully happened yet. It reportedly received FDA "green light" status years ago, but funding the required $50M+ for a multi-center, 3,000-person trial has been the primary hurdle. Smaller trials such as MILES (Metformin in Longevity Study) and MET-PREVENT (2025/2026 data) reportedly showed mixed results: metformin improved certain hallmarks of aging such as inflammation, but did not significantly improve muscle mass or walking speed in already-frail seniors. The description suggests metformin might work better as a preventative than as a rescue therapy.
Supporting source [1]
How to interpret this
This is based only on the supplied video description; the video and transcript were not reviewed. TAME is described as planned or not fully conducted, so no results are reported. The description gives no details on design beyond the composite endpoint, sample size and funding figure, and the smaller-trial findings are summarized without numbers or full methods.
Based on the creator’s description; the full video and transcript were not analyzed.
Source & supporting passages
North Texas Medical Anti Aging Center · youtube.com · March 1, 2026